PLX241018C2500
- 0.05
- 0.000.00%
Protalix Biotherapeutics Newsroom
Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Protalix BioTherapeutics Announced That It Has Repaid In Full Its 7.50% Senior Secured Convertible Promissory Notes Financed Entirely With Available Cash
Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts?
Protalix BioTherapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q2 EPS Results.
Protalix BioTherapeutics, Inc. (PLX) Q2 2024 Earnings Call Transcript Summary
Protalix BioTherapeutics Q2 24 Earnings Conference Call At 8:30 AM ET
Protalix Biotherapeutics | 10-Q: Q2 2024 Earnings Report
Earnings Flash (PLX) PROTALIX BIOTHERAPEUTICS Reports Q2 Revenue $13.5M, Vs. Street Est of $12.5M
Protalix BioTherapeutics GAAP EPS of -$0.03 Misses by $0.05, Revenue of $13.47M Beats by $0.97M
Protalix BioTherapeutics 2Q Rev $13.5M >PBD.DU
Protalix BioTherapeutics 2Q Loss/Shr 3c >PBD.DU
Here's the Major Earnings Before the Open Tomorrow
Protalix BioTherapeutics Q2 Earnings Preview
Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024
Protalix BioTherapeutics to Host In-Person Investor Day to Discuss Current Treatment Landscapes and Clinical Results for Fabry Disease and Uncontrolled Gout
Protalix BioTherapeutics to Present at the 2024 BIO International Convention
Protalix BioTherapeutics Inc (PLX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Earnings Call Summary | Protalix Biotherapeutics(PLX.US) Q1 2024 Earnings Conference
Novavax, Macrogenics, Biofrontera Among Healthcare Movers
NOTV, BFRI and CPOP Among Pre-market Losers